Tryptophan metabolism and oxidative stress in patients with Huntington's disease
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Abnormalities in the kynurenine pathway may play a role in Huntington's disease (HD). In this study, tryptophan depletion and loading were used to investigate changes in blood kynurenine pathway metabolites, as well as markers of inflammation and oxidative stress in HD patients and healthy controls. Results showed that the kynurenine : tryptophan ratio was greater in HD than controls in the baseline state and after tryptophan depletion, indicating increased indoleamine dioxygenase activity in HD. Evidence for persistent inflammation in HD was provided by elevated baseline levels of C‐reactive protein, neopterin and lipid peroxidation products compared with controls. The kynurenate : kynurenine ratio suggested lower kynurenine aminotransferase activity in patients and the higher levels of kynurenine in patients at baseline, after depletion and loading, do not result in any differences in kynurenic acid levels, providing no supportive evidence for a compensatory neuroprotective role for kynurenic acid. Quinolinic acid showed wide variations in blood levels. The lipid peroxidation data indicate a high level of oxidative stress in HD patients many years after disease onset. Levels of the free radical generators 3‐hydroxykynurenine and 3‐hydroxyanthranilic acid were decreased in HD patients, and hence did not appear to contribute to the oxidative stress. It is concluded that patients with HD exhibit abnormal handling of tryptophan metabolism and increased oxidative stress, and that these factors could contribute to ongoing brain dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“S100B is elevated in patients with Alzheimer’s disease and Down’s syndrome (Griffin et al. 1989), and is increased following ischaemic stroke (Buttner et al. 1997; Wunderlich et al. 1999).”
BackgroundReplication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,286
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 961
Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnett, S. B., & Morton, A. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-03248.1999 · Cited by 947
Perkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849
Self-citationEndogenous kynurenines as targets for drug discovery and development
Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768
Self-citationBlood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism
Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 761
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 2×
“The discovery that quinolinic acid was an endogenous agonist at N-methyl-D-aspartate (NMDA) receptors (Stone and Perkins 1981; Stone 2001; Stone and Darlington 2002) producing excitotoxic lesions after localized injection (Schwarcz et al. 1983) while kynurenic acid was an antagonist (Perkins and…”
BackgroundSelf-citationNeopterin as a Marker for Immune System Activation
Murr, C., Widner, B., Wirleitner, B., & Fuchs, D. (2002) · Current Drug Metabolism · doi:10.2174/1389200024605082 · Cited by 738
Gershov, D., Kim, S., Brot, N., & Elkon, K. B. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1353 · Cited by 695
HEYES, M. P., SAITO, K., CROWLEY, J. S., DAVIS, L. E., DEMITRACK, M. A., DER, M., DILLING, L. A., ELIA, J., KRUESI, M. J. P., LACKNER, A., et al. (1992) · Brain · doi:10.1093/brain/115.5.1249 · Cited by 680
Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00615-3 · Cited by 595
Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J. P., & Difiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 540
Huntingtin aggregation and toxicity in Huntington's disease
Bates, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13304-1 · Cited by 525
Oxidative stress in Huntington’s disease
Browne, S. E., Ferrante, R. J., & Beal, M. F. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00216.x · Cited by 508
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
Beal, M., Ferrante, R., Swartz, K., & Kowall, N. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-06-01649.1991 · Cited by 499
II. Excitotoxic models for neurodegenerative disorders
Schwarcz, R., Foster, A. C., French, E. D., Whetsell, W. O., & Köhler, C. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90148-6 · Cited by 466
Okuda, S., Nishiyama, N., Saito, H., & Katsuki, H. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010299.x · Cited by 462
Human macrophages convert l-tryptophan into the neurotoxin quinolinic acid
Heyes, M. P., Saito, K., & Markey, S. P. (1992) · Biochemical Journal · doi:10.1042/bj2830633 · Cited by 447
Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH
Burke, J. R., Enghild, J. J., Martin, M. E., Jou, Y.-S., Myers, R. M., Roses, A. D., Vance, J. M., & Strittmatter, W. J. (1996) · Nature Medicine · doi:10.1038/nm0396-347 · Cited by 428
NMDA Receptor Losses in Putamen from Patients with Huntington's Disease
Young, A. B., Greenamyre, J. T., Hollingsworth, Z., Albin, R., D'Amato, C., Shoulson, I., & Penney, J. B. (1988) · Science · doi:10.1126/science.2841762 · Cited by 395
Huntington aggregates may not predict neuronal death in Huntington's disease.
Kuemmerle, S., Gutekunst, C., Klein, A., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · PubMed · Cited by 362
Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
Tabrizi, S. J., Workman, J., Hart, P. E., Mangiarini, L., Mahal, A., Bates, G., Cooper, J. M., & Schapira, A. H. V. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<80::aid-ana13>3.0.co;2-k · Cited by 351
Birch, P. J., Grossman, C. J., & Hayes, A. G. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90367-6 · Cited by 318
Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., & Bird, E. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb03143.x · Cited by 311
Huntingtin aggregates may not predict neuronal death in Huntington's disease
Kuemmerle, S., Gutekunst, C.-A., Klein, A. M., Li, X.-J., Li, S.-H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<842::aid-ana6>3.0.co;2-o · Cited by 308
Kynurenines in the CNS: from endogenous obscurity to therapeutic importance
Stone, T. W. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00032-0 · Cited by 306
Self-citationOkuda, S., Nishiyama, N., Saito, H., & Katsuki, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12553 · Cited by 301
NMDA receptor function in mouse models of Huntington disease
Cepeda, C., Ariano, M. A., Calvert, C. R., Flores‐Hernández, J., Chandler, S. H., Leavitt, B. R., Hayden, M. R., & Levine, M. S. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1244 · Cited by 274
S-100 Protein: Serum Marker of Focal Brain Damage After Ischemic Territorial MCA Infarction
Büttner, T., Weyers, S., Postert, T., Sprengelmeyer, R., & Kuhn, W. (1997) · Stroke · doi:10.1161/01.str.28.10.1961 · Cited by 259
Wunderlich, M. T., Ebert, A. D., Kratz, T., Goertler, M., Jost, S., & Herrmann, M. (1999) · Stroke · doi:10.1161/01.str.30.6.1190 · Cited by 251
Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease
Bogdanov, M. B., Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., & Beal, M. F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00689.x · Cited by 248
Studies of the Suspension Stability of the Blood in Pulmonary Tuberculosis1
WESTERGREN, A. (1921) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1921.tb15179.x · Cited by 243
Impaired Synaptic Plasticity in Mice Carrying the Huntington's Disease Mutation
Usdin, M. T., Shelbourne, P. F., Myers, R. M., & Madison, D. V. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.839 · Cited by 230
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex
Flint Beal, M., Matson, W. R., Storey, E., Milbury, P., Ryan, E. A., Ogawa, T., & Bird, E. D. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90191-m · Cited by 218
Activated human microglia produce the excitotoxin quinolinic acid
Espey, M. G., Chernyshev, O. N., Reinhard, J. F., Namboodiri, M. A. A., & Colton, C. A. (1997) · NeuroReport · doi:10.1097/00001756-199701200-00011 · Cited by 195
Hervé, C., Beyne, P., Jamault, H., & Delacoux, E. (1996) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/0378-4347(95)00341-x · Cited by 185
3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.
Schwarcz, R., Okuno, E., White, R. J., Bird, E. D., & Whetsell, W. O. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4079 · Cited by 184
Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin
Chen, N., Luo, T., Wellington, C., Metzler, M., McCutcheon, K., Hayden, M. R., & Raymond, L. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721890.x · Cited by 180
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.
Widner, B., Leblhuber, F., & Fuchs, D. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200014 · Cited by 171
Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line
Eastman, C. L., & Guilarte, T. R. (1989) · Brain Research · doi:10.1016/0006-8993(89)90216-3 · Cited by 161
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease
Pearson, S. J., & Reynolds, G. P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90749-w · Cited by 155
Pérez‐Severiano, F., Ríos, C., & Segovia, J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02082-5 · Cited by 146
Jauch, D., Urbańska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J., Whetsell, W. O., & Schwarcz, R. M. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)00280-2 · Cited by 127
Vécsei, L., Miller, J. M., Macgarvey, U., & Beal, M. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90184-y · Cited by 118
The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine
Eastman, C. L., & Guilarte, T. R. (1990) · Neurochemical Research · doi:10.1007/bf01101711 · Cited by 114
Brain Quinolinic Acid in Huntington's Disease
Reynolds, G. P., Pearson, S. J., Halket, J. M., & Sandier, M. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb02503.x · Cited by 109
Burns, L. H., Pakzaban, P., Deacon, T. W., Brownell, A., Tatter, S. B., Jenkins, B. G., & Isacson, O. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00431-4 · Cited by 107
Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model
Guidetti, P., Reddy, P. H., Tagle, D. A., & Schwarcz, R. M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00956-3 · Cited by 97
Activated Immune System in Patients with Huntington's Disease
Leblhuber, F., Walli, J., Jellinger, K., Tilz, G. P., Widner, B., Laccone, F. A., & Fuchs, D. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.132 · Cited by 89
3-Hydroxykynurenine Toxicity on the Rat Striatum In Vivo
Nakagami, Y., Saitō, H., & Katsuki, H. (1996) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.71.183 · Cited by 88
Huether, G., Hajak, G., Reimer, A., Pöeggeler, B., Blömer, M., Rodenbeck, A., & Rüther, E. (1992) · Psychopharmacology · doi:10.1007/bf02247718 · Cited by 86
Hughes, P. E., Alexi, T., Williams, C. E., CLARK, R. G., & Gluckman, P. D. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00724-6 · Cited by 85
Heilbronn, L. K., & Clifton, P. M. (2002) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00187-0 · Cited by 80
Transgenic models of Huntington'sdisease
Sathasivam, K., Hobbs, C., Mangiarini, L., Mahal, A., Turmaine, M., Doherty, P., Davies, S. W., & Bates, G. P. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0447 · Cited by 72
Increase in Kynurenic Acid in Huntington's Disease Motor Cortex
Connick, J. H., Carla�, V., Moroni, F., & Stone, T. W. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb02552.x · Cited by 58
Self-citationSchwarz, M., Block, F., Töpper, R., Sontag, K. ‐., & Noth, J. (1992) · Annals of Neurology · doi:10.1002/ana.410320309 · Cited by 55
Moja, E. A., Restani, P., Corsini, E., Stacchezzini, M. C., Assereto, R., & Galli, C. L. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90600-g · Cited by 54
Miller, J. M., Macgarvey, U., & Beal, M. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90186-b · Cited by 53
Backer, J. F. A. D., Mak, R. P., Bacquer, D. D., Renterghem, L. V., Verbraekel, E., Kornitzer, M., & Backer, G. D. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00602-5 · Cited by 53
The effect of lowering plasma tryptophan on food selection in normal males
Young, S. N., Tourjman, V., Teff, K. L., Pihl, R. O., & Anderson, G. H. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90326-7 · Cited by 40
Popoli, P., Pèzzola, A., Domenici, M. R., Sagratella, S., Diana, G., Caporali, M. G., Bronzetti, E., Vega, J., & de Carolis, A. S. (1994) · Brain Research Bulletin · doi:10.1016/0361-9230(94)90109-0 · Cited by 36
Jauch, D., Sethy, V. H., Weick, B. G., et al. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90171-x · Cited by 34
Effects of striatal excitotoxicity on Huntingtin-like immunoreactivity
Tatter, S. B., Galpern, W. R., Hoogeveen, A. T., et al. (1995) · Neuroreport · doi:10.1097/00001756-199505300-00013 · Cited by 31
Poston, M. R., Bailey, M. S., Schwarcz, R. M., & Shipley, M. T. (1991) · The Journal of Comparative Neurology · doi:10.1002/cne.903110307 · Cited by 18
Neurochemical-clinical correlates in Huntington's disease--applications of brain banking techniques.
Reynolds, G. P., & Pearson, S. J. (1993) · PubMed · Cited by 12
Cited by
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H.-Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 515
Metadata
- Authors
- Stoy, N., Mackay, G. M., Forrest, C. M., Christofides, J., Egerton, M., Stone, T. W., & Darlington, L. G.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2005-04-04
- Volume
- 93
- Issue
- 3
- Pages
- 611-623
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2157059809
- Cited by
- 310
- References
- 68
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.